Cholinergic regulation of VIP gene expression in human neuroblastoma cells

Brain Research

Volumn 775, Issue 1-2, 1997, Pages 99-106

  Kristensen, Bo ^a   Georg, Birgitte ^a   Fahrenkrug, Jan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gene expression; mRNA; Muscarinic receptor; Neuroblastoma cell; Peptide processing; Vasoactive intestinal polypeptide

Indexed keywords

CARBACHOL; INOSITOL 1,4,5 TRISPHOSPHATE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL ULTRASTRUCTURE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN PROCESSING;

BRAIN NEOPLASMS; CARBACHOL; CYCLOHEXIMIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; NEUROBLASTOMA; NEUROPEPTIDES; PARASYMPATHETIC NERVOUS SYSTEM; PARASYMPATHOMIMETICS; PROTEIN SYNTHESIS INHIBITORS; RADIOIMMUNOASSAY; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031446588     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00966-9     Document Type: Article

References (28)

1. Abens J., Westlind A., Bartfaï T. Chronic atropine treatment causes increase in VIP receptors in rat cerebral cortex. Peptides. 5:1984;375-377.
2. Adler E.M., Fink J.S. Calcium regulation of vasoactive intestinal polypeptide mRNA abundance in SH-SY5Y human neuroblastoma cells. J. Neurochem. 61:1993;727-737.
3. Agoston D., Colburn S., Kranjiak K., Washek J.A. Distinct regulation of vasoactive intestinal peptide (VIP) expression at mRNA and peptide levels in human neuroblastoma cells. Neurosci. Lett. 139:1992;213-216.
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
5. Dunér-Engström M., Larsson O., Fredholm B.B., Lundblad L., Fahrenkrug J., Lundberg J.M. Effects of acute and long-term atropine treatment on levels, release and response to VIP and PHI in the submandibular gland of cat and rat. Acta Physiol. Scand. 146:1992;357-367.
6. Ebeid A.M., Attia R.R., Sundaram P., Fischer J.E. Release of vasoactive intestinal peptide in the central nervous system in man. Am. J. Surg. 137:1979;123-127.
7. Eckenstein F., Baughman R.W. Two types of cholinergic innervation in cortex, one co-localized with vasoactive intestinal polypeptide. Nature. 309:1984;153-155.
8. Fahrenkrug J., Schaffalitzky de Muckadell O.B. Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma. J. Lab. Clin. Med. 89:1977;1379-1388.
9. Fahrenkrug J., Scaffalitzky de Muckadell O.B. Distribution of vasoactive intestinal polypeptide (VIP) in the porcine central nervous system. J. Neurochem. 31:1978;1445-1451.
10. Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol. Toxicol. 72:1993;354-363.
11. Fahrenkrug J., Emson P.C. Characterization and distribution of peptides from the vasoactive intestinal peptide precursor in the normal human brain. J. Neurochem. 53:1989;1142-1148.
12. Georg B., Wulff B.S., Fahrenkrug J. Characterization of the effects of retinoic acid on vasoactive intestinal polypeptide gene expression in neuroblastoma cells. Endocrinology. 135(12):1900;1455-1463.
13. Hayakawa Y., Obata K.-I., Itoh N., Yanaihara N., Okamoto H. Cyclic AMP regulation of pro-vasoactive intestinal polypeptide/PHM-27 synthesis in human neuroblastoma cells. J. Biol. Chem. 259:1984;9207-9211.
14. Hedlund B., Abens J., Bartfaï T. Vasoactive intestinal polypeptide and muscarinic receptors; supersensitivity induced by long-term atropine treatment. Science. 220:1983;519-521.
15. T. Hökfelt, M. Schultzberg, J.M. Lundberg, K. Fuxe, V. Mutt, J. Fahrenkrug, S.I. Said, Distribution of vasoactive intestinal polypeptide in the central and peripheral nervous systems as revealed by immunohistochemistry, in: S.I. Said (Ed.), Advances in Peptide Hormone Research: Vasoactive Intestinal Peptide, Raven, New York, 1982, pp. 65-90.
16. Itoh N., Obata K.-I., Yanaihara N., Okamoto H. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature. 304:1983;547-548.
17. Lapchak P.A., Beaudet A. Cholinergic regulation of vasoactive intestinal polypeptide content and release in rat frontal cortex and hippocampus. J. Neurochem. 55:1990;1340-1345.
18. Lundberg J.M., Änggård A., Fahrenkrug J., Hökfelt T., Mutt V. Vasoactive intestinal polypeptide in the cholinergic neurons of exocrine glands: functional significance of coexisting transmitters for vasodilation and secretion. Proc. Natl. Acad. Sci. USA. 77:1980;1651-1655.
19. Petit J.-M., Denoroy L., Jouvet M. Effects of chronic atropine administration on regional vasoactive intestinal polypeptide concentrations in rat brain. Eur. J. Pharmacol. 212:1992;79-85.
20. Pincus D.W., DiCicco-Bloom E.M., Black I.B. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature. 343:1990;564-567.
21. Rao M.S., Symes A., Malik N., Shoyab M., Fink J.S., Landis S.C. Oncostatin M regulates VIP expression in a human neuroblastoma cell line. Neuroreport. 3:1992;865-868.
22. Said S.I., Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 225:1970;863-864.
23. Symes A., Lewis S., Corpus L., Rajan P., Hyman S.E., Fink J.S. STAT proteins participate in the regulation of the vasoactive intestinal peptide gene by the ciliary neurotrophic factor family of cytokines. Mol. Endocrinol. 8:1994;1750-1763.
24. Waelbroeck M., Camus J., Tastenoy M., Christophe J. 80% of muscarinic receptors expressed by NB-OK 1 human neuroblastoma cell line show high affinity for pirenzepine and are comparable to rat hippocampus M1 receptors. FEBS Lett. 226:1988;287-290.
25. J.A. Waschek, Environmental and hormonal control of vasoactive intestinal peptide (VIP) gene expression and changes observed in clinical and experimental pathological conditions, in: A.J. Turner (Ed.), Neuropeptide Gene Expression, Portland, London, 1994, pp. 107-132.
26. Wulff B.S., Georg B., Fahrenkrug J. Expression and characterization of VIP and two VIP mutants in NIH 3T3 cells. FEBS Lett. 341:1994;43-48.
27. Yanaihara N., Suzuki T., Sato H., Hoshino M., Okaru Y., Yanaihara C. Dibutyryl cAMP stimulation of production and release of VIP-like immunoreactivity in a human neuroblastoma cell line. Biomed. Res. 2:1981;728-734.
28. Yiangou Y., Di Marzo V., Spokes R.A., Panico M., Morris H.R., Bloom S.R. Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. J. Biol. Chem. 262:1987;14010-14013.